GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
1 . A NK-92 cell modified to express a Fc receptor on a surface of the cell, wherein the NK-92 cell modified to express a Fc receptor is competent for ADCC.
2 - 32 . (canceled)
33 . A method for detecting cytolytic and apoptosis-inducing activity, comprising:
exposing a target cell in the absence of antibodies to a NK-92 cell expressing an Fc receptor; and
monitoring the target cell for cytotoxicity, cytolysis or apoptosis.
34 - 35 . (canceled)
36 . A method of assaying the efficacy of an antibody to treat a tumor, infection or other lesion, comprising:
administering the antibody to the subject;
administering modified NK-92 cells expressing an Fc receptor to the subject; and
monitoring the tumor, infection or lesion,
wherein the efficacy of the antibody correlates with suppression of the tumor, infection or lesion in the subject.
37 - 44 . (canceled)
45 . A method of treating a subject, the subject having a tumor, infection or other lesion, the method comprising:
administering to the subject antibodies that specifically bind to the tumor, infection or other lesion; and
administering to the subject modified NK-92 cells expressing an Fc receptor.
46 - 59 . (canceled)